BOEHRINGER INGELHEIM EXTENDING COLLABORATION GENENTECHvia

BOEHRINGER INGELHEIM EXTENDING COLLABORATION GENENTECHvia an agreement for commercialization of tumor necrosis factors (TNF's) in Europe and "certain other markets," Genentech noted in a Feb. 28 press release.The firm says it has now developed two tumor necrosis factors, which are preclinicals as anticancer agents. The latest Boehringer/Genentech licensing agreement covering tumor necrosis was anounced along with Boehringer's acquisition of a 4.9% stake at the biotech firm for $40 mil. Genentech announced that Boehringer purchased 750,000 shares of Genentech's 15.1 mil common shares in a private placement at $53.41 a share. Genentech CEO Robert Swanson commented: "Boehringer Ingelheim is an important partner among our many corporate partners around the world." Boehringer's investment complements similar investments in Genentech by companies such as Lubrizol Corp., Corning Glass Works, Alfa-Laval and Fluor Corp. With the marketing agreement for tumor necrosis factors, Boehringer now has three such agreements with Genentech. The firm has rights to market human tissue-type plasminogen activator (t-PA) in Europe, the Middle East, Africa, South America and parts to Australia. In addition, Boehringer has European marketing rights to gamma interferon, which is in Phase II clinicals as an anticancer agent. In addition to the Boehringer investment, Genentech said it plans to file a registration statement with the Securities & Exchange Commission for a public offering of 1 mil. shares of common. The firm said it plans to use the proceeds for capital expenditures and additions to working capital. Genentech stock finished the month of February at 51-1/2 after climbing over 17 points since the beginning of the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.